20
2
Cat No. | Product Name | Synonyms | Targets |
---|---|---|---|
T26817 | Bim-BLK-A | Bim Blocker A,Compound A,Bim BLK A,BimBLKA | |
Bim-BLK-A efficiently blocks Bim-induced apoptosis after Bax is activated on the mitochondria. The cellular target of Bim-BLK-A was identified to be the succinate dehydrogenase subunit B (SDHB) protein of complex II of t... | |||
T63959 | BLK-IN-1 | ||
BLK-IN-1 is a selective, covalent inhibitor of B-lymphotyrosine kinase (BLK) and BTK with IC50 values of 18.8 nM and 20.5 nM, respectively. BLK-IN-1 can be used in cancer research. | |||
T73366 | BLK-IN-2 | ||
BLK-IN-2 is a potent, selective, and irreversible inhibitor of B-Lymphoid tyrosine kinase (BLK), demonstrating significant efficacy with an IC50 of 5.9 nM. Additionally, it exhibits an inhibitory effect on BTK (Bruton's ... | |||
T9072 | Tuxobertinib | BDTX-189 | EGFR , HER , BTK , RIP kinase |
Tuxobertinib (BDTX-189) is a potent and selective inhibitor of allosteric EGFR and HER2 oncogenic mutations(KDs of 0.2, 0.76, 13 and 1.2 nM for EGFR, HER2, BLK and RIPK2, reapectively). BDTX-189 exhibits anticancer activ... | |||
T6078 | Saracatinib | AZD0530 | EGFR , Src , BTK , Autophagy |
Saracatinib (AZD0530) (AZD0530) is an effective Src inhibitor (IC50: 2.7 nM), and effective to Lck, Fyn, Lyn, Blk, Fgr and c-Yes. | |||
T14692 | BMX-IN-1 | BMX kinase inhibitor | BTK |
BMX-IN-1 (BMX kinase inhibitor) is a selective inhibitor of bone marrow tyrosine kinase on chromosome X (BMX, IC50 = 8 nM) and the related Bruton’s tyrosine kinase (BTK, IC50 = 10.4 nM), but BMX-IN-1 is more than 47-656 ... | |||
T71819 | RK-20448 | ||
RK-20448 is an ATP-competitive inhibitor of Lck, Src, KDR/VEGF2R, and Tie-2. It also inhibits BLK, Csk, Fyn, and Lyn. RK-20448 is the cis isomer of A-419259 | |||
T39129 | BMS-986143 | ||
BMS-986143, an orally active, reversible BTK inhibitor with an IC50 value of 0.26 nM, is designed for autoimmune disease research. Additionally, it targets TEC, BLK, BMX, TXK, FGR, YES1, and ITK, exhibiting IC50s of 3 nM... | |||
T74642 | DB1113 | ||
DB1113 (Example 24) is a bifunctional compound designed for the targeted degradation of various kinases. It effectively degrades a range of kinases, including ABL1, ABL2, BLK, CDK11B, CDK4, CSK, EPHA3, FER, GAK, LIMK1, M... | |||
T7819 | TAS0728 | EGFR , HER | |
TAS0728 is a HER2 inhibitor, with antitumor activity | |||
T5138 | BMS-986142 | BTK | |
BMS-986142 is a potent and highly selective reversible BTK inhibitor (IC50: 0.5 nM). | |||
T10802 | CHMFL-EGFR-202 | EGFR | |
CHMFL-EGFR-202 is a potent, irreversible inhibitor of EGFR mutant kinase (IC50s: 5.3 nM and 8.3 nM for drug-resistant mutant EGFR T790M and WT EGFR kinases). | |||
T74644 | DB0614 | ||
DB0614 (Example 21) is a bifunctional compound designed for the targeted degradation of kinases, effectively breaking down a wide array of kinases including AAK1, AURKA, BMP2K, CAMKK1, CDK16, CML, CDK6, EIF2AK2, FER, GAK... | |||
T12542 | Rilzabrutinib | PRN1008 | EGFR , Others , HER , BTK |
Rilzabrutinib (PRN1008) is a reversible covalent, selective and oral active inhibitor of Bruton’s Tyrosine Kinase (BTK)(IC50 of 1.3 nM). | |||
T1835 | Ibrutinib | PCI-32765 | Tyrosine Kinases , Src , BTK , Ligands for Target Protein for PROTAC |
Ibrutinib (PCI-32765) is an irreversible inhibitor of BTK (IC50: 0.5 nM) that selectively blocks B cell activation. | |||
T13564L | AZ7550 hydrochloride | AZ7550 hydrochloride (1421373-99-0 free base) | EGFR , IGF-1R |
AZ7550 hydrochloride (AZ7550 hydrochloride ), an active metabolite of AZD9291, inhibits the activity of IGF1R (IC50: 1.6 μM). | |||
T13564 | AZ7550 | MLK , FAK , EGFR , FLT , Tyrosine Kinases , PYK2 , MNK , IGF-1R , ACK , BTK , ALK , Drug Metabolite | |
AZ7550, an active metabolite of AZD9291, inhibits the activity of IGF1R (IC50: 1.6 μM). | |||
T16578 | PRN694 | Others | |
PRN694 shows extended target residence time on ITK and RLK, enabling durable attenuation of effector cells in vitro and in vivo. PRN694 is an irreversible, highly selective, and effective covalent interleukin-2-inducible... | |||
T10801 | CHMFL-ABL/KIT-155 | CHMFL-ABL-KIT-155 | c-Kit |
CHMFL-ABL/KIT-155 is a highly potent and orally active type II ABL/c-KIT dual kinase inhibitor (IC50s: 46 nM/75 nM). It arrests cell cycle progression and induces apoptosis. | |||
T18049 | Ibrutinib-biotin | Others | |
Ibrutinib-biotin is a probe that consists of Ibrutinib linked to biotin via a long chain linker, has an IC50 of 0.755-1.02 nM for BTK. |
Cat No. | Product Name | Species | Expression System |
---|---|---|---|
TMPJ-00307 | BLK Protein, Human, Recombinant (His) | Human | E. coli |
Tyrosine-Protein Kinase Blk (BLK) contains one protein kinase domain, one SH2 domain and one SH3 domain. BLK is a non-receptor tyrosine kinase, which is involved in B-lymphocyte development, differentiation and signaling... | |||
TMPY-04388 | BLK Protein, Human, Recombinant (GST) | Human | Baculovirus Insect Cells |
Tyrosine-protein kinase Blk, also known as B lymphocyte kinase, p55-Blk and BLK, is a member of theprotein kinase superfamily, Tyr protein kinase family and SRC subfamily. BLK / p55-Blk is expressed in lymphatic organ... |